Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update

Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026Expands European commercialization readiness, including surgeon training and regulatory approval of new manufacturing …